Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Presentation symbols : Vcnx save search
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease
Published: 2023-03-23 (Crawled : 12:20) - biospace.com/
VCNX | $4.8 4.5K
|
Health Technology
|
| O: -3.01%
H: 2.54%
C: -1.03%
disease alzheimer’s presentation
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
Published: 2022-07-29 (Crawled : 11:00) - ir.vaccinex.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: 0.97%
H: 1.37%
C: 0.96%
conference disease alzheimer’s presentation pepinemab international study
Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
Published: 2022-04-25 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: -0.8%
H: 2.42%
C: -1.61%
activmab drug conference technology presentation
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
Published: 2022-03-09 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: 1.83%
H: 18.92%
C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer vaccine phase 2b
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
Published: 2022-03-09 (Crawled : 23:00) - globenewswire.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: 1.83%
H: 18.92%
C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer head and neck vaccine phase 2b
Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference
Published: 2021-05-19 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: -5.44%
H: 6.68%
C: 3.9%
vaccine conference presentation
Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
Published: 2021-03-11 (Crawled : 13:06) - ir.vaccinex.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: 2.27%
H: 5.4%
C: 5.08%
vaccine conference presentation
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
Published: 2020-10-26 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 4.5K
|
Health Technology
|
| O: 6.91%
H: 2.99%
C: -0.5%
vaccine presentation
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.